Phoenix VA Health Care System, 650 E Indian School Rd CS111E, Phoenix, AZ, 85012, USA.
Isoformix Inc., 9830 S. 51st Suite B-113, Phoenix, AZ, 85044, USA.
Atherosclerosis. 2023 Sep;380:117214. doi: 10.1016/j.atherosclerosis.2023.117214. Epub 2023 Aug 7.
Higher truncated-to-native proteoform ratios of apolipoproteins (apo) C-I (C-I'/C-I) and C-II (C-II'/C-II) are associated with less atherogenic lipid profiles. We examined prospective relationships of C-I'/C-II and C-II'/C-II with coronary heart disease (CHD) and coronary artery calcium (CAC).
ApoC-I and apoC-II proteoforms were measured by mass spectrometry immunoassay in 5790 MESA baseline plasma samples. CHD events (myocardial infarction, resuscitated cardiac arrest, fatal CHD, n = 434) were evaluated for up to 17 years. CAC was measured 1-4 times over 10 years for incident CAC (if baseline CAC = 0), and changes (follow-up adjusted for baseline) in CAC score and density (if baseline CAC>0).
C-II'/C-II was inversely associated with CHD (n = 434 events) after adjusting for non-lipid cardiovascular risk factors (Hazard ratio: 0.89 [95% CI: 0.81-0.98] per SD), however, the association was attenuated after further adjustment for HDL levels (0.93 [0.83-1.03]). There was no association between C-I'/C-I and CHD (0.98 [0.88-1.08]). C-II'/C-II was positively associated with changes in CAC score (3.4% [95%CI: 0.6, 6.3]) and density (6.3% [0.3, 4.2]), while C-I'/C-I was inversely associated with incident CAC (Risk ratio: 0.89 [95% CI: 0.81, 0.98]) in fully adjusted models that included plasma lipids. Total apoC-I and apoC-II concentrations were not associated with CHD, incident CAC or change in CAC score.
Increased apoC-II truncation was associated with reduced CHD, possibly explained by differences in lipid metabolism. Increased apoC-I and apoC-II truncations were also associated with less CAC progression and/or development of denser coronary plaques.
载脂蛋白(apo)C-I(C-I'/C-I)和 C-II(C-II'/C-II)的截断型原蛋白比值较高与致动脉粥样硬化脂质谱较低有关。我们研究了 C-I'/C-II 和 C-II'/C-II 与冠心病(CHD)和冠状动脉钙(CAC)的前瞻性关系。
通过质谱免疫测定法在 5790 例 MESA 基线血浆样本中测量 apoC-I 和 apoC-II 原蛋白。评估了长达 17 年的 CHD 事件(心肌梗死、复苏性心脏骤停、致命性 CHD,n=434)。在 10 年内对 CAC 进行 1-4 次测量,如果基线 CAC=0,则评估新发 CAC,如果基线 CAC>0,则评估 CAC 评分和密度的变化(根据基线调整随访)。
在调整非脂质心血管危险因素后,C-II'/C-II 与 CHD(n=434 例事件)呈负相关(风险比:每标准差 0.89 [95%CI:0.81-0.98]),然而,在进一步调整 HDL 水平后,相关性减弱(0.93 [0.83-1.03])。C-I'/C-I 与 CHD 之间无关联(0.98 [0.88-1.08])。C-II'/C-II 与 CAC 评分的变化呈正相关(3.4%[95%CI:0.6,6.3%])和密度(6.3%[0.3,4.2]),而 C-I'/C-I 与完全调整模型中的新发 CAC 呈负相关(风险比:0.89 [95%CI:0.81,0.98]),该模型包括血浆脂质。总 apoC-I 和 apoC-II 浓度与 CHD、新发 CAC 或 CAC 评分变化均无关。
apoC-II 截断增加与 CHD 减少相关,可能与脂质代谢差异有关。apoC-I 和 apoC-II 截断增加也与 CAC 进展和/或更密集的冠状动脉斑块形成减少相关。